Facing the bleeding risk of caplacizumab in postpartum immune thrombotic thrombocytopenic purpura in constrained resource settings
A visual overview of postpartum immune-mediated TTP (iTTP) treated with caplacizumab in a constrained resource setting. Emphasises timely diagnosis, multidisciplinary management and adapted therapy despite restricted access to ADAMTS13/von Willebrand factor testing and the unavailability of rituximab for iTTP treatment.
Authors
- José Rojas‐Suarez (ORCID: https://orcid.org/0000-0003-0310-3235)
- David Correa‐Maldonado
- Diego Cabarcas‐Castilla
- Arnold Castro‐Giraldo
- Gustavo Ahumada‐Pla
Institutions
- University of Cartagena (CO)
- Corporación Universitaria Rafael Nuñez (CO)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1111/bjh.20249
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00